Camillo Aliberti1, Riccardo Carandina1, Donatella Sarti2, Enrico Pizzirani1, Gaetano Ramondo1, Umberto Cillo3, Stefano Guadagni4, Giammaria Fiorentini2. 1. Oncology Radiodiagnostics Department, Oncology Institute of Veneto, Institute for the Research & Treatment of Cancer (IRCC), 35128 Padova, Italy. 2. Onco-Ematology Department, Azienda Ospedaliera 'Ospedali Riuniti Marche Nord', 61122 Pesaro, Italy. 3. Surgical and Gastroenterological Sciences Dept, University of Padova, 35128 Padova, Italy. 4. Department of Applied Clinical Sciences & Biotechnology, University of L'Aquila, 7100 L'Aquila, AQ, Italy, and Alma Mater Europaea - ECM, Slovenska ulica 17, Maribor, Slovenja.
Abstract
AIM: Primary objectives of the study were to assess the safety of transarterial chemoembolization (TACE) using DC Bead LUMI™ for the treatment of hepatocellular carcinoma and beads distribution after TACE. PATIENTS/ METHODS: This was a prospective observational cohort study. The study included 44 hepatocellular carcinoma patients who were treated with TACE using DC Bead LUMI. Beads distribution was monitored 1 h after TACE by CT scan. RESULTS: TACE had no intraprocedural complications. Observed side effects were of mild intensity and included pain in 5 (11%), fever in 4 (9%) and vomiting in 2 (5%) patients. Most patients (89%) reported no adverse event. Non-target distribution was observed in only two cases (5%). CONCLUSION: DC Bead LUMI allowed assessing in real time their distribution. This could prevent non-target infusion and reduce toxicity.
AIM: Primary objectives of the study were to assess the safety of transarterial chemoembolization (TACE) using DC Bead LUMI™ for the treatment of hepatocellular carcinoma and beads distribution after TACE. PATIENTS/ METHODS: This was a prospective observational cohort study. The study included 44 hepatocellular carcinomapatients who were treated with TACE using DC Bead LUMI. Beads distribution was monitored 1 h after TACE by CT scan. RESULTS:TACE had no intraprocedural complications. Observed side effects were of mild intensity and included pain in 5 (11%), fever in 4 (9%) and vomiting in 2 (5%) patients. Most patients (89%) reported no adverse event. Non-target distribution was observed in only two cases (5%). CONCLUSION: DC Bead LUMI allowed assessing in real time their distribution. This could prevent non-target infusion and reduce toxicity.
Authors: Andrew L Lewis; Sean L Willis; Matthew R Dreher; Yiqing Tang; Koorosh Ashrafi; Bradford J Wood; Elliot B Levy; Karun V Sharma; Ayele H Negussie; Andrew S Mikhail Journal: Future Oncol Date: 2018-06-26 Impact factor: 3.404
Authors: Dominik F Vollherbst; Theresa Gockner; Thuy Do; Kerstin Holzer; Carolin Mogler; Paul Flechsig; Alexander Harms; Christopher L Schlett; Philippe L Pereira; Götz M Richter; Hans U Kauczor; Christof M Sommer Journal: PLoS One Date: 2018-07-09 Impact factor: 3.240
Authors: John Reicher; Sebastian Mafeld; Georgia Priona; Helen L Reeves; Derek M Manas; Ralph Jackson; Peter Littler Journal: Cardiovasc Intervent Radiol Date: 2019-08-27 Impact factor: 2.740
Authors: Andrew L Lewis; Marcus Caine; Pedro Garcia; Koorosh Ashrafi; Yiqing Tang; Lorcan Hinchcliffe; Wei Guo; Zainab Bascal; Hugh Kilpatrick; Sean L Willis Journal: J Biomed Mater Res B Appl Biomater Date: 2020-06-23 Impact factor: 3.368
Authors: Ayele H Negussie; Quirina M B de Ruiter; Hugh Britton; Danielle R Donahue; Quentin Boffi; Young-Seung Kim; William F Pritchard; Chrit Moonen; Gert Storm; Andrew L Lewis; Bradford J Wood Journal: Sci Rep Date: 2021-01-12 Impact factor: 4.996
Authors: Cyrus W Beh; Yingli Fu; Clifford R Weiss; Charles Hu; Aravind Arepally; Hai-Quan Mao; Tza-Huei Wang; Dara L Kraitchman Journal: Lab Chip Date: 2020-09-01 Impact factor: 6.799